Incannex Healthcare has commissioned the University of Western Australia’s Centre for Sleep Science as an additional site for an ongoing trial investigating the effects of its cannabinoid-based drug candidate IHL-42X on adults with obstructive sleep apnoea.
Patient recruitment will run in parallel with an ongoing trial at The Alfred Hospital in Melbourne, meaning it is now considered a multi-site study with additional medical and scientific staff contributing to its operation.
Incannex received ethics approval for the trial in September 2020.
ASX-listed Emyria has entered a trading halt pending an announcement regarding regulatory registration of its Openly remote health monitoring application.
The halt will remain in place until the start of trading on Thursday, May 13 or until an announcement is released to the market.